

Round table discussion:

"Challenges and Opportunities in PROTAC vs Small Molecules Development"

Panelist:

Dr Malin Lemurell (AstraZeneca, Sweden)



Dr. Malin Lemurell is the Head of Medicinal Chemistry in Cardiovascular, Renal and Metabolism at AstraZeneca Gothenburg, Sweden. Since 2013 she has been leading the department with 60+ Medicinal Chemists supporting the portfolio across multiple chemical modalities. Malin received her PhD at the Gothenburg University in 1999 in organic chemistry. After post-doctoral studies with Prof. Barry Sharpless at The Scripps Research Institute in California, she joined AstraZeneca as a scientist and has subsequently held various leadership roles. Dr. Lemurell is an author of multiple publications and patents, including patents of eg. Odevixibat and AZD5718 (Phase II). Her current interests include drug design across small molecules and New Modalities incl PROTACs, targeted drug delivery, drugging RNA using small molecules and to develop drug hunters of the future.